Clinical characteristics and outcomes of phase I cancer patients with CCNE1 amplification: MD Anderson experiences
Published 2022 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Clinical characteristics and outcomes of phase I cancer patients with CCNE1 amplification: MD Anderson experiences
Authors
Keywords
-
Journal
Scientific Reports
Volume 12, Issue 1, Pages -
Publisher
Springer Science and Business Media LLC
Online
2022-05-24
DOI
10.1038/s41598-022-12669-5
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Phase I studies of vorinostat with ixazomib or pazopanib imply a role of antiangiogenesis-based therapy for TP53 mutant malignancies
- (2020) Yudong Wang et al. Scientific Reports
- CCNE1 Amplification as a Predictive Biomarker of Chemotherapy Resistance in Epithelial Ovarian Cancer
- (2020) Justin W. Gorski et al. Diagnostics
- CCNE1 amplification is associated with poor prognosis in patients with triple negative breast cancer
- (2019) Zi-Ming Zhao et al. BMC CANCER
- Cyclin E1 Expression and Palbociclib Efficacy in Previously Treated Hormone Receptor–Positive Metastatic Breast Cancer
- (2019) Nicholas C. Turner et al. JOURNAL OF CLINICAL ONCOLOGY
- Validation of a Plasma-Based Comprehensive Cancer Genotyping Assay Utilizing Orthogonal Tissue- and Plasma-Based Methodologies
- (2018) Justin I. Odegaard et al. CLINICAL CANCER RESEARCH
- Cyclin E1 and cyclin-dependent kinase 2 are critical for initiation, but not for progression of hepatocellular carcinoma
- (2018) Roland Sonntag et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Outcome analysis of Phase I trial patients with metastatic KRAS and/or TP53 mutant non-small cell lung cancer
- (2018) Yudong Wang et al. Oncotarget
- Cyclin-Dependent Kinase 2 Inhibitors in Cancer Therapy: An Update
- (2018) Solomon Tadesse et al. JOURNAL OF MEDICINAL CHEMISTRY
- Antiangiogenesis and gene aberration-related therapy may improve overall survival in patients with concurrent KRAS and TP53 hotspot mutant cancer
- (2017) Zhijie Wang et al. Oncotarget
- CCNE1 copy-number gain and overexpression identify ovarian clear cell carcinoma with a poor prognosis
- (2016) Ayse Ayhan et al. MODERN PATHOLOGY
- Phase I study of pazopanib and vorinostat: a therapeutic approach for inhibiting mutant p53-mediated angiogenesis and facilitating mutant p53 degradation
- (2015) S. Fu et al. ANNALS OF ONCOLOGY
- CCNE1 amplification is associated with aggressive potential in endometrioid endometrial carcinomas
- (2015) KENTARO NAKAYAMA et al. INTERNATIONAL JOURNAL OF ONCOLOGY
- Cyclin-dependent kinase 2 is an ideal target for ovary tumors with elevated cyclin E1 expression
- (2015) Liu Yang et al. Oncotarget
- Cyclin E amplification/overexpression is associated with poor prognosis in gastric cancer
- (2014) M. Alsina et al. ANNALS OF ONCOLOGY
- Cyclin E involved in early stage carcinogenesis of esophageal adenocarcinoma by SNP DNA microarray and immunohistochemical studies
- (2014) Zhongren Zhou et al. BMC GASTROENTEROLOGY
- Clinical massively parallel next-generation sequencing analysis of 409 cancer-related genes for mutations and copy number variations in solid tumours
- (2014) R R Singh et al. BRITISH JOURNAL OF CANCER
- “Platinum resistant” ovarian cancer: What is it, who to treat and how to measure benefit?
- (2014) Alison Davis et al. GYNECOLOGIC ONCOLOGY
- MEK inhibition in non-small cell lung cancer
- (2014) Thomas E. Stinchcombe et al. LUNG CANCER
- Cyclin E1 Deregulation Occurs Early in Secretory Cell Transformation to Promote Formation of Fallopian Tube-Derived High-Grade Serous Ovarian Cancers
- (2013) A. M. Karst et al. CANCER RESEARCH
- Resistance to CDK2 Inhibitors Is Associated with Selection of Polyploid Cells in CCNE1-Amplified Ovarian Cancer
- (2013) D. Etemadmoghadam et al. CLINICAL CANCER RESEARCH
- Cyclin E1 (CCNE1) as independent positive prognostic factor in advanced stage serous ovarian cancer patients – A study of the OVCAD consortium
- (2013) Dietmar Pils et al. EUROPEAN JOURNAL OF CANCER
- Integrative Analysis of Complex Cancer Genomics and Clinical Profiles Using the cBioPortal
- (2013) J. Gao et al. Science Signaling
- Potential tumorigenic programs associated with TP53 mutation status reveal role of VEGF pathway
- (2012) H Joshi et al. BRITISH JOURNAL OF CANCER
- Meta-analysis for cyclin E in lung cancer survival
- (2012) Li-nian Huang et al. CLINICA CHIMICA ACTA
- Survival of 1,181 Patients in a Phase I Clinic: The MD Anderson Clinical Center for Targeted Therapy Experience
- (2012) J. Wheler et al. CLINICAL CANCER RESEARCH
- Cyclin-Dependent Kinase Suppression by WEE1 Kinase Protects the Genome through Control of Replication Initiation and Nucleotide Consumption
- (2012) H. Beck et al. MOLECULAR AND CELLULAR BIOLOGY
- Value of integrated positron emission tomography revised using a phantom study to evaluate malignancy grade of lung adenocarcinoma
- (2010) Haruhiko Nakayama et al. CANCER
- Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial
- (2010) Yung-Jue Bang et al. LANCET
- Serous tubal intraepithelial carcinoma upregulates markers associated with high-grade serous carcinomas including Rsf-1 (HBXAP), cyclin E and fatty acid synthase
- (2010) Ann Smith Sehdev et al. MODERN PATHOLOGY
- New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1)
- (2008) E.A. Eisenhauer et al. EUROPEAN JOURNAL OF CANCER
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExploreDiscover Peeref hubs
Discuss science. Find collaborators. Network.
Join a conversation